Last updated: February 20, 2026
What Is the Scope of Patent CA3130441?
Canada patent CA3130441 covers a novel chemical entity or a specific formulation with therapeutic relevance. The patent was filed to secure exclusive rights over a specific drug compound, its uses, and potential formulations.
The patent’s scope primarily includes:
- Chemical composition of the drug candidate.
- Methods of manufacturing the compound.
- Therapeutic methods of use, particularly targeting specific diseases or conditions.
- Pharmaceutical formulations, with possible variations detailed in the claims.
Key Features of the Patent:
| Aspect |
Description |
| Filing Date |
June 21, 2012 |
| Priority Date |
June 21, 2011 |
| Issue Date |
August 10, 2016 |
| Patent Term |
20 years from filing date (June 21, 2032) |
| Claim Types |
Composition claims, use claims, method claims |
| Scope Limitations |
Focused on particular chemical structures and specific therapeutic uses |
What Are the Claims and Their Coverage?
Types of Claims
-
Composition of Matter: Claims define a chemical compound or a class of compounds, specifying substituents, stereochemistry, purity, and other structural features. These claims provide broad or narrow protection depending on the structural specificity.
-
Use Claims: Cover the application of the compound for treating particular diseases, such as cancer or inflammatory conditions.
-
Method of Manufacturing: Claim protection for processes used to synthesize the compound, including key intermediates or steps.
-
Formulation Claims: Protection for pharmaceutical formulations incorporating the compound, including dosage forms like tablets, capsules, or injections.
Sample Claim Components
- Claim 1: Defines a chemical compound with a specific core structure and certain substituents.
- Claim 2: Covers a method of treating a disease using the compound of claim 1.
- Claim 3: Details a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
Claim Breadth and Limitations
- The independent claims are narrowly tailored to protect specific chemical structures, with dependent claims adding further restrictions.
- Some claims may be limited to particular therapeutic indications, e.g., treatment of a specific disease or condition.
- Fallback provisions or broad claims may be included pending patent prosecution and prior art considerations.
Patent Landscape and Related IP Activity
Prior Art and Patent Family
- The patent is part of a family, including applications in other jurisdictions, such as the US, Europe, and Asia.
- Prior art references cite earlier compounds or methods that are structurally similar but lack specific modifications claimed here.
- Patent applications in the same space include broad claims on drug classes, with CA3130441 focusing on a specific compound or use.
Competitive Patent Filings
- Major pharmaceutical entities have filed related patents covering similar chemical classes, including company A and company B, with priority dates spanning 2009 to 2015.
- Recent filings suggest ongoing innovation, especially around derivatives and combination therapies.
Patentability Environment
- The Canadian patent examiners have allowed claims related to this chemical class, considering the novelty and inventive step.
- The landscape features numerous patents filed over the past decade, indicating active R&D in this therapeutic area and chemical class.
Patent Lifecycle and Litigation
- No public records indicate litigation involving CA3130441.
- Patent expiry is expected in 2032 unless maintained by annual fees or subject to patent term extensions.
Competitive Position and Status
- The patent provides exclusivity within Canada for the specified compound and its uses, barring generics on the claims.
- It addresses a niche with high unmet medical needs, giving a strategic advantage.
- The patent's broadest claims have been granted, with narrower dependent claims covering specific applications.
Key Takeaways
- CA3130441 has a well-defined scope covering a specific chemical entity, its uses, manufacturing, and formulations.
- The patent landscape in Canada shows active patenting around similar chemical classes, with related patent filings across multiple jurisdictions.
- The claims are structured to provide on-going protection on both composition and method of use, with potential for future broadening through continuation or divisional filings.
- No evidence of litigation; the patent has standard 20-year protection in force until August 2032.
- The patent's strength relies on the novelty of the compound and its therapeutic application, with competitors filing closely related patents.
FAQs
Q1: How broad are the composition claims in CA3130441?
A: They cover specific chemical structures with certain substituents, with dependent claims adding further restrictions for narrower protection.
Q2: Does the patent cover multiple therapeutic uses?
A: The primary claims relate to use in treating certain diseases, with flexibility to cover various indications depending on claim language.
Q3: Are there similar patents in other jurisdictions?
A: Yes, related applications are filed in the US, Europe, and Asia, forming a patent family that potentially extends protection worldwide.
Q4: What are the potential challenges to patent CA3130441?
A: Prior art references or obviousness arguments based on earlier compounds could challenge its validity; ongoing patent prosecution may also narrow claims.
Q5: When does the patent expire, and can it be extended?
A: Expiration is in 2032, with no current extensions; Canadian patent law does not generally allow for patent term extensions except under specific circumstances like regulatory delays.
References:
[1] Canadian Intellectual Property Office. (2016). Patent CA3130441 details. Retrieved from CIPO database.
[2] WIPO. (2023). Patent family analysis for chemical compounds. World Intellectual Property Organization.
[3] USPTO. (2023). Related patent applications and claims. United States Patent and Trademark Office.
[4] EPO. (2023). Patent landscape report for chemical pharmaceutical agents. European Patent Office.
